Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1985 Sep;202(3):278–282. doi: 10.1097/00000658-198509000-00002

Implantable infusion pump management of insulin resistant diabetes mellitus.

H Buchwald, E P Chute, F J Goldenberg, C R Hitchcock, B J Hoogwerf, J J Barbosa, W M Rupp, T D Rohde
PMCID: PMC1250895  PMID: 4037902

Abstract

Diabetes mellitus with resistance to insulin administered subcutaneously or intramuscularly (DRIASM) is a rare and brittle form of Type I diabetes, found predominantly in young females and characterized by inadequate glycemic response to subcutaneous or intramuscular insulin administration. DRIASM leads to frequent ketoacidosis and obligatory hospitalization for administration of intravenous insulin. The use of a totally implantable infusion pump effected dramatic improvement in the treatment of five patients with this difficult form of diabetes. Frequency of clinical ketoacidosis was reduced from 37 episodes per year to 0.4 episodes per year (99%), and average in-hospital days per month were reduced from 20.8 days to 2.2 days (89%) with a mean follow-up period of 14.4 months. Cost savings were approximately +10,000 per patient month. Quality of life was greatly improved for these individuals.

Full text

PDF
278

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bayliss J. Brittle diabetes: long-term control with a portable, continuous, intravenous insulin infusion system. Br Med J (Clin Res Ed) 1981 Nov 7;283(6301):1207–1209. doi: 10.1136/bmj.283.6301.1207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blackshear P. J., Dorman F. D., Blackshear P. L., Jr, Varco R. L., Buchwald H. A permanently implantable self-recycling low flow constant rate multipurpose infusion pump of simple design. Surg Forum. 1970;21:136–137. [PubMed] [Google Scholar]
  3. Blackshear P. J., Dorman F. D., Blackshear P. L., Jr, Varco R. L., Buchwald H. The design and initial testing of an implantable infusion pump. Surg Gynecol Obstet. 1972 Jan;134(1):51–56. [PubMed] [Google Scholar]
  4. Buchwald H., Grage T. B., Vassilopoulos P. P., Rohde T. D., Varco R. L., Blackshear P. J. Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump. Cancer. 1980 Mar 1;45(5):866–869. doi: 10.1002/1097-0142(19800301)45:5<866::aid-cncr2820450507>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  5. Buchwald H., Rohde T. D., Schneider P. D., Varco R. L., Blackshear P. J. Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis. Surgery. 1980 Oct;88(4):507–516. [PubMed] [Google Scholar]
  6. Campbell I. W., Kritz H., Najemnik C., Hagmueller G., Irsigler K. Treatment of type I diabetic with subcutaneous insulin resistance by a totally implantable insulin infusion device ("Infusaid"). Diabetes Res. 1984 Jul;1(2):83–88. [PubMed] [Google Scholar]
  7. Clements R. S., Jr, Vourganti B. Fatal diabetic ketoacidosis: major causes and approaches to their prevention. Diabetes Care. 1978 Sep-Oct;1(5):314–325. doi: 10.2337/diacare.1.5.314. [DOI] [PubMed] [Google Scholar]
  8. Dandona P., Foster M., Healey F., Greenbury E., Beckett A. G. Low-dose insulin infusions in diabetic patients with high insulin requirements. Lancet. 1978 Aug 5;2(8084):283–285. doi: 10.1016/s0140-6736(78)91688-4. [DOI] [PubMed] [Google Scholar]
  9. Defective absorption of injected insulin. Lancet. 1978 Sep 30;2(8092 Pt 1):741–741. [PubMed] [Google Scholar]
  10. Diabetes resistant to subcutaneous insulin: effect of aprotinin. N Engl J Med. 1981 Dec 3;305(23):1413–1414. doi: 10.1056/NEJM198112033052313. [DOI] [PubMed] [Google Scholar]
  11. Flier J. S. Insulin receptors and insulin resistance. Annu Rev Med. 1983;34:145–160. doi: 10.1146/annurev.me.34.020183.001045. [DOI] [PubMed] [Google Scholar]
  12. Freidenberg G. R., White N., Cataland S., O'Dorisio T. M., Sotos J. F., Santiago J. V. Diabetes responsive to intravenous but not subcutaneous insulin: effectiveness of aprotinin. N Engl J Med. 1981 Aug 13;305(7):363–368. doi: 10.1056/NEJM198108133050702. [DOI] [PubMed] [Google Scholar]
  13. Maberly G. F., Wait G. A., Kilpatrick J. A., Loten E. G., Gain K. R., Stewart R. D., Eastman C. J. Evidence for insulin degradation by muscle and fat tissue in an insulin resistant diabetic patient. Diabetologia. 1982 Oct;23(4):333–336. doi: 10.1007/BF00253740. [DOI] [PubMed] [Google Scholar]
  14. McElduff A., Eastman C. J., Haynes S. P., Bowen K. M. Apparent insulin resistance due to abnormal enzymatic insulin degradation: a new mechanism for insulin resistance. Aust N Z J Med. 1980 Feb;10(1):56–61. doi: 10.1111/j.1445-5994.1980.tb03421.x. [DOI] [PubMed] [Google Scholar]
  15. Misbin R. I., Almira E. C., Cleman M. W. Insulin degradation in serum of a patient with apparent insulin resistance. J Clin Endocrinol Metab. 1981 Feb;52(2):177–180. doi: 10.1210/jcem-52-2-177. [DOI] [PubMed] [Google Scholar]
  16. Müller W. A., Taillens C., Léreret S., Berger M., Philippe J., Halban P. A., Offord R. E. Resistance against subcutaneous insulin successfully managed with aprotinin. Lancet. 1980 Jun 7;1(8180):1245–1246. doi: 10.1016/s0140-6736(80)91698-0. [DOI] [PubMed] [Google Scholar]
  17. Paulsen E. P., Courtney J. W., 3rd, Duckworth W. C. Insulin resistance caused by massive degradation of subcutaneous insulin. Diabetes. 1979 Jul;28(7):640–645. doi: 10.2337/diab.28.7.640. [DOI] [PubMed] [Google Scholar]
  18. Pickup J. C., Bilous R. W., Keen H. Aprotinin and insulin resistance. Lancet. 1980 Jul 12;2(8185):93–94. doi: 10.1016/s0140-6736(80)92976-1. [DOI] [PubMed] [Google Scholar]
  19. Pickup J., Williams G., Johns P., Keen H. Clinical features of brittle diabetic patients unresponsive to optimized subcutaneous insulin therapy (continuous subcutaneous insulin infusion). Diabetes Care. 1983 May-Jun;6(3):279–284. doi: 10.2337/diacare.6.3.279. [DOI] [PubMed] [Google Scholar]
  20. Rupp W. M., Barbosa J. J., Blackshear P. J., McCarthy H. B., Rohde T. D., Goldenberg F. J., Rublein T. G., Dorman F. D., Buchwald H. The use of an implantable insulin pump in the treatment of type II diabetes. N Engl J Med. 1982 Jul 29;307(5):265–270. doi: 10.1056/NEJM198207293070501. [DOI] [PubMed] [Google Scholar]
  21. Schade D. S., Drumm D. A., Duckworth W. C., Eaton R. P. The etiology of incapacitating, brittle diabetes. Diabetes Care. 1985 Jan-Feb;8(1):12–20. doi: 10.2337/diacare.8.1.12. [DOI] [PubMed] [Google Scholar]
  22. Schade D. S., Eaton R. P., Warhol R. M., Gregory J. A., Doberneck R. C. Subcutaneous peritoneal access device for type I diabetic patients nonresponsive to subcutaneous insulin. Diabetes. 1982 May;31(5 Pt 1):470–473. doi: 10.2337/diab.31.5.470. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES